Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication

What is it about?

The combination of pre- and post-neoadjuvant endocrine treatment Oncotype DX Recurrence Scores predicted disease-free survival better than either alone. The combined Recurrence Score differentiated early recurrence in the high-risk group from mid/late recurrence in the intermediate-risk group. We propose that possible differential treatment strategies including addition of chemotherapy and extension of endocrine therapy could be applied based on the risk categories indicated by the combined Recurrence Score once validated by larger studies.

Featured Image